What is HaystackMRD?
Founded in 2021 and headquartered in Baltimore, Maryland, HaystackMRD operates at the intersection of advanced biotechnology and clinical oncology. The company specializes in the development of highly sensitive molecular residual disease (MRD) assays, which are critical for monitoring cancer treatment efficacy and detecting recurrence at the earliest possible stages. By providing clinicians with actionable data, HaystackMRD enables more personalized and effective therapeutic interventions. Its market position is defined by a commitment to precision medicine, utilizing cutting-edge genomic analysis to transform how oncologists approach long-term patient management and therapy optimization.
How much funding has HaystackMRD raised?
HaystackMRD has raised a total of $56M across 1 funding round:
Series A
$56M
Series A (2022): $56M with participation from Exact Ventures, Bruker, Alexandria Venture Investments, and Catalio Capital Management
Key Investors in HaystackMRD
Bruker
Bruker Corporation is a global leader in scientific instrumentation and analytical technologies, providing high-performance diagnostic solutions across the pharmaceutical and biotechnology sectors.
Catalio Capital Management
Catalio Capital Management is a specialized investment firm focused on breakthrough biomedical technologies, leveraging a network of venture partners to support category-defining healthcare companies.
Exact Ventures
Exact Ventures is an independent market intelligence and advisory firm that provides deep analytical insights into emerging technology markets and industry transitions.
What's next for HaystackMRD?
Looking ahead, the strategic deployment of these funds will likely focus on expanding the company's clinical validation studies and accelerating the commercialization of its diagnostic platform. As HaystackMRD transitions from its initial development phase into a period of rapid scaling, the focus will shift toward integrating its technology into standard oncology workflows and securing broader regulatory approvals. The backing from specialized healthcare investors provides not only the necessary financial runway but also access to a deep network of biomedical expertise, which will be instrumental in navigating the complex regulatory and competitive landscape of the precision diagnostics market. Future growth will likely be driven by strategic partnerships and the continued refinement of its molecular detection capabilities.
See full HaystackMRD company page
